Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients

Thrombosis and Haemostasis

Volumn 117, Issue 3, 2017, Pages 519-528

  Bluecher, Annemarie ^a   Dos Santos, Sascha Meyer ^a,b   Ferreirós, Nerea ^a   Labocha, Sandra ^a   Meyer Dos Santos, Isabel Maria Rodrigues ^a   Picard Willems, Bettina ^a   Harder, Sebastian ^a   Singer, Oliver C ^a,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Acute; Antithrombins; Factor Xa antagonists inhibitors; Phenprocoumon; Stroke; Whole blood coagulation time

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; ARGATROBAN; CLOPIDOGREL; DABIGATRAN; HEPARIN; PHENPROCOUMON; RIVAROXABAN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CEREBROVASCULAR ACCIDENT; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; ELECTROSPRAY; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MICROFLUIDIC ANALYSIS; MULTIPLE REACTION MONITORING; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTHROMBIN TIME; QUADRUPOLE MASS SPECTROMETRY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURFACE ACOUSTIC WAVES INDUCED CLOTTING TIME; TANDEM MASS SPECTROMETRY; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LABORATORY AUTOMATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; REPRODUCIBILITY; TIME FACTOR; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AUTOMATION, LABORATORY; BLOOD COAGULATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DABIGATRAN; DRUG MONITORING; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PHENPROCOUMON; PREDICTIVE VALUE OF TESTS; PYRAZOLES; PYRIDONES; REPRODUCIBILITY OF RESULTS; RIVAROXABAN; STROKE; TANDEM MASS SPECTROMETRY; TIME FACTORS; TREATMENT OUTCOME; WHOLE BLOOD COAGULATION TIME;

EID: 85014323884     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-08-0619     Document Type: Article

References (36)

1. Rizos T, et al. Oral anticoagulants--a frequent challenge for the emergency management of acute ischaemic stroke. Cerebrovasc Dis 2012; 34: 411-418.
2. Bouget J, Oger E. Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Thromb Res 2015; 136: 1190-1194.
3. Douxfils J, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thrombosis Res 2012; 130: 956-966.
4. Douxfils J, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
5. McGlasson DL, et al. Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy. Blood Coagul Fibrinol 2008; 19: 513-517.
6. Barrett YC, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
7. Dale BJ, et al. Laboratory measurement of the direct oral anticoagulants. Br J Haematol 2016; 172: 315-336.
8. Hillarp A, et al. Effects of the oral direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost 2014; 12: 1545-1553.
9. Samama MM, et al. Monitoring plasma levels of factor Xa inhibitors: how. Why and when? Expert Rev Hematol 2013; 6: 155-164.
10. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-772.
11. Bonar R, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016; 48: 60-71.
12. Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013; 121: 4032-4035.
13. Lindhoff-Last E, et al. Laboratory testing of rivaroxaban in routine clinical practice: when. how. and which assays. Ann Med 2013; 45: 423-429.
14. Marshall RS. Progress in Intravenous Thrombolytic Therapy for Acute Stroke. JAMA Neurol 2015; 72: 928-934.
15. Meyer dos Santos S, et al. A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants. Biomicrofluidics 2013; 7: 56502.
16. Ng VL. Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med 2009; 29: 253-263.
17. Ray MJ, Hawson GA. A comparison of two APTT reagents which use silica activators. Clin Lab Haematol 1989; 11: 221-232.
18. van den Besselaar AM, et al. Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin. Blood Coagul Fibrinol 1993; 4: 895-903.
19. Graff J, et al. Effects of the oral direct factor xa inhibitor rivaroxaban on plateletinduced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398-1407.
20. Mueck W, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53: 1-16.
21. Jourdi G, et al. Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. Thromb Haemost 2015; 114: 78-86.
22. Epple C, Steiner T. Acute stroke in patients on new direct oral anticoagulants: how to manage. how to treat? Expert Opin Pharmacother 2014; 15: 1991-2001.
23. Ishihara H, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. J Stroke Cerebrovasc Dis 2014; 23: e457-459.
24. van Hooff RJ, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischaemic stroke in a patient treated with rivaroxaban. Clin Neurol Neurosurg 2014; 122: 133-134.
25. Neal AJ, et al. Intravenous thrombolysis for acute ischaemic stroke in the setting of rivaroxaban use. J Clin Neurosci 2014; 21: 2013-2015.
26. De Smedt A, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with apixaban. Int J Stroke 2014; 9: E31.
27. Landais A, Ginoux C. Intravenous thrombolysis for acute ischaemic stroke in a patient receiving rivaroxaban. J Stroke Cerebrovasc Dis 2015; 24: e73-74.
28. Ebner M, et al. Point-of-care testing of coagulation in patients treated with nonvitamin K antagonist oral anticoagulants. Stroke 2015; 46: 2741-2747.
29. Moll J, et al. Micro-optical prototyping of a surface acoustic wave-based pointofcare coagulation assay and first application in anticoagulated patients. Int J Clin Pharmacol Ther 2016; 54: 177-184.
30. Cuker A, et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64: 1128-1139.
31. Koscielny J, Rutkauskaite E. Rivaroxaban and hemostasis in emergency care. Emerg Med Internat 2014; 2014: 935474.
32. Steiner T, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs) apixaban dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412.
33. Hillarp A, et al. Effects of the oral. direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-139.
34. Di Minno A, et al. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 2013; 39: 840-846.
35. Samama MM, et al. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: Results of a multicenter field trial. Clin Appl Thromb Hem 2012; 18: 150-158.
36. Jauch EC, et al. Guidelines for the early management of patients with acute ischaemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947.